Adjunct Interpersonally Focused Psychodynamic Group Psychotherapy for Residual Depression Symptoms

NCT02449499 | Terminated DMC

• 1 other identifier: IRB-32272
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Depression and anxiety disorders, even when treated according to standard of care consisting of individual treatment with medication and/or therapy, can be associated with significant residual impact on quality of life. The purpose of this research is carry out an observational study of an existing clinical treatment, adjunctive interpersonally focused psychodynamic group therapy, to determine if this can improve quality of life for patients who have residual symptoms of chronic depression and anxiety.

Conditions

Depression; Anxiety

Outcome Measures

Primary Outcomes (1)

• psychological and general well-being index

  6 months

Secondary Outcomes (2)

• ASQ (adult attachment style questionnaire)

  6 months

• ICI (interpersonal communication inventory)

  6 months

Study Arms (2)

therapy

patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy

control

patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed with major depression, adjustment disorder, generalized anxiety disorder, panic disorder, social phobia, or other depression NOS diagnosis currently in treatment with individual psychotherapist, continuing to experience symptoms even after at least six months in standard individual treatment with a psychiatrist or psychologist.

You may qualify if:

• MINI diagnosis of major depression, adjustment disorder, generalized anxiety disorder, panic disorder, social phobia, or depression not otherwise specified (NOS)
• PHQ9 \<20 and/or GAD7\>5 despite minimum of 6 months of prior psychiatric treatment
• Poor interpersonal, social, academic, work or home function based on clinical assessment and subjective self-report
• Effective engagement with group therapy task as assessed during standardized initial screening which is to demonstrate a willingness and ability to engage in an effective therapeutic manner with others in the group
• Ongoing treatment by primary individual psychotherapist
• Insurance with behavioral health coverage accepted at Stanford clinics

You may not qualify if:

• Active serious medical conditions
• Traumatic Brain Injury (TBI), dementia, developmental delay or severe cognitive impairment
• Psychotic or substance abuse issues
• On newly prescribed psychiatric medication \<30 days on stable target dose
• Currently in acute depressive episode
• Personality disorder
• Suicidality
• Inability to speak/understand English fluently

Sponsors & Collaborators

• Stanford University: lead

Study Sites (1)

Stanford Psychiatry and Behavioral Science

Palo Alto, California, 94304, United States

Location

MeSH Terms

Conditions

Depression; Anxiety Disorders

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Mental Disorders

Study Officials

• Carrie Holmberg, MD, PhD

  Stanford Psychiatry and Behavioral Science

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: protocol director

Study Record Dates

• First Submitted: April 7, 2015
• First Posted: May 20, 2015
• Study Start: April 1, 2015
• Primary Completion: October 1, 2015
• Study Completion: October 1, 2016
• Last Updated: October 17, 2016

Record last verified: 2016-10

Locations

US (1)